Adaptimmune Therapeutics - רווח נקי למניה ב-12 החודשים האחרונים ADAP

Adaptimmune is implementing its unique SPEAR technology to reprogram immunity for the treatment of solid tumors. Revenues are based on strategic partnerships, while future growth relies on the launch of drugs for rare types of cancer. The current commercialization phase of breakthrough immuno-oncology methods is driving the price action. The EPS YoY TTM growth value demonstrates business resilience, while 54.80 captures the current state of the parameter.

The investment attractiveness of Adaptimmune (ADAP) is based on the commercialization of the SPEAR platform and the scaling of sarcoma therapy production. This indicator calculates the annual dynamics of GAAP net income per share, allowing for the exclusion of one-time Non-GAAP adjustments. By analyzing the annual EPS (TTM) growth statistics, an investor can assess the company's real fundamental margin of safety and the risk of divergence between reported earnings and market price.